caa a22 4500 46573782X CHVBK 20180323111759.0 cr unu---uuuuu 170327e19900501xx s 000 0 eng 10.1007/BF02253730 doi (NATIONALLICENCE)springer-10.1007/BF02253730 Steady-state pharmacokinetics of controlled release and immediate release formulations of remoxipride in patients with chronic schizophrenia [Elektronische Daten] [D. Tench, S. Soni, T. Ashwood, G. Movin] Twenty-four stable, chronic schizophrenic inpatients were entered in a double-blind crossover study designed to compare single dose and steady state pharmacokinetic profiles of an immediate release formulation (IR) 200 mg BID and a controlled release formulation (CR) of remoxipride 400 mg once daily. The rate of absorption of remoxipride CR was significantly lower than the IR formulation andt max was prolonged from 1.3 to 7.9 h after a single dose and from 2.2 to 6.0 h after repeated dosing. Although the single dose of remoxipride CR was twice as large as the single dose of the IR, theC max was similar for both formulations after a single dose. However, theC max at steady state was slightly lower for CR. There was significantly less fluctuation in plasma concentrations at steady state with the CR formulation, although the average plasma concentration of remoxipride IR and CR was similar. The mean relative bioavailability with regard to the amount of remoxipride absorbed after remoxipride CR 400 mg once daily compared to IR 200 mg BID was 97%. It was concluded that the CR formulation is suitable for a once-daily administration from a pharmacokinetic point of view. Springer-Verlag, 1990 Chronic schizophrenia nationallicence Maintenance neuroleptic therapy nationallicence Remoxipride nationallicence Controlled release formulation nationallicence Pharmacokinetics nationallicence Tench D. Consultant Psychiatrist, Salford Health Authority, Hope and Prestwich Hospitals, Eccles Old Road, M6 8HD, Salford, UK aut Soni S. Consultant Psychiatrist, Salford Health Authority, Hope and Prestwich Hospitals, Eccles Old Road, M6 8HD, Salford, UK aut Ashwood T. Astra Clinical Research Unit, EH1 3EP, Edinburgh, UK aut Movin G. Astra Research Centre, S-Sodertalje, Sweden aut Psychopharmacology Springer-Verlag 101/1(1990-05-01), 132-136 0033-3158 101:1<132 1990 101 213 https://doi.org/10.1007/BF02253730 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF02253730 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Tench D. Consultant Psychiatrist, Salford Health Authority, Hope and Prestwich Hospitals, Eccles Old Road, M6 8HD, Salford, UK aut NATIONALLICENCE 700 1- Soni S. Consultant Psychiatrist, Salford Health Authority, Hope and Prestwich Hospitals, Eccles Old Road, M6 8HD, Salford, UK aut NATIONALLICENCE 700 1- Ashwood T. Astra Clinical Research Unit, EH1 3EP, Edinburgh, UK aut NATIONALLICENCE 700 1- Movin G. Astra Research Centre, S-Sodertalje, Sweden aut NATIONALLICENCE 773 0- Psychopharmacology Springer-Verlag 101/1(1990-05-01), 132-136 0033-3158 101:1<132 1990 101 213 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer